Cargando…

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

PURPOSE: To investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors. METHODS: The participants were divided into three groups: 386 healthy women (control group),...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fawen, Shen, Jing, Wang, Jianwei, Cai, Pengwei, Huang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968799/
https://www.ncbi.nlm.nih.gov/pubmed/29861641
http://dx.doi.org/10.2147/CMAR.S155693
_version_ 1783325846518366208
author Chen, Fawen
Shen, Jing
Wang, Jianwei
Cai, Pengwei
Huang, Yi
author_facet Chen, Fawen
Shen, Jing
Wang, Jianwei
Cai, Pengwei
Huang, Yi
author_sort Chen, Fawen
collection PubMed
description PURPOSE: To investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors. METHODS: The participants were divided into three groups: 386 healthy women (control group), 262 patients with benign ovarian tumors (the benign group), and 196 patients with malignant pelvic tumors (the malignant group). The serum levels of HE4, CA125, CA19-9, and CEA were analyzed by electrochemiluminescent immunoassay. RESULTS: It showed that serum levels of HE4, CA125, CA19-9, and CEA of patients with malignant ovarian tumors were significantly higher than those in the control group and benign group (P<0.01). HE4 had a high specificity (96.56%) in malignant ovarian tumors. The tumor markers HE4, CA125, CA19-9, and CEA had a sensitivity of 63.78%, 62.75%, 35.71%, and 38.78%, respectively. The combined use of two or more tumor markers (parallel test) had a higher diagnostic sensitivity but lower specificity than a single tumor marker. The combined efficiency of HE4 and CA125 was the highest, with a sensitivity and specificity of 80.10% and 69.08%, respectively. HE4 and CA125 combined with the Risk of Ovarian Malignancy Algorithm provided an efficient means of screening and diagnosis of ovarian malignancies. The diagnostic sensitivity increased to 88.52% when three or four tumor markers were used but showed no significant difference compared with the combination of HE4 and CA125 (P>0.05). CONCLUSION: The combination of three or four tumor markers did not improve the diagnostic efficacy when compared with the combination of HE4 and CA125.
format Online
Article
Text
id pubmed-5968799
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59687992018-06-01 Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors Chen, Fawen Shen, Jing Wang, Jianwei Cai, Pengwei Huang, Yi Cancer Manag Res Original Research PURPOSE: To investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors. METHODS: The participants were divided into three groups: 386 healthy women (control group), 262 patients with benign ovarian tumors (the benign group), and 196 patients with malignant pelvic tumors (the malignant group). The serum levels of HE4, CA125, CA19-9, and CEA were analyzed by electrochemiluminescent immunoassay. RESULTS: It showed that serum levels of HE4, CA125, CA19-9, and CEA of patients with malignant ovarian tumors were significantly higher than those in the control group and benign group (P<0.01). HE4 had a high specificity (96.56%) in malignant ovarian tumors. The tumor markers HE4, CA125, CA19-9, and CEA had a sensitivity of 63.78%, 62.75%, 35.71%, and 38.78%, respectively. The combined use of two or more tumor markers (parallel test) had a higher diagnostic sensitivity but lower specificity than a single tumor marker. The combined efficiency of HE4 and CA125 was the highest, with a sensitivity and specificity of 80.10% and 69.08%, respectively. HE4 and CA125 combined with the Risk of Ovarian Malignancy Algorithm provided an efficient means of screening and diagnosis of ovarian malignancies. The diagnostic sensitivity increased to 88.52% when three or four tumor markers were used but showed no significant difference compared with the combination of HE4 and CA125 (P>0.05). CONCLUSION: The combination of three or four tumor markers did not improve the diagnostic efficacy when compared with the combination of HE4 and CA125. Dove Medical Press 2018-05-22 /pmc/articles/PMC5968799/ /pubmed/29861641 http://dx.doi.org/10.2147/CMAR.S155693 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Fawen
Shen, Jing
Wang, Jianwei
Cai, Pengwei
Huang, Yi
Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title_full Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title_fullStr Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title_full_unstemmed Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title_short Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
title_sort clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of he4, ca125, ca19-9, and cea in ovarian tumors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968799/
https://www.ncbi.nlm.nih.gov/pubmed/29861641
http://dx.doi.org/10.2147/CMAR.S155693
work_keys_str_mv AT chenfawen clinicalanalysisoffourserumtumormarkersin458patientswithovariantumorsdiagnosticvalueofthecombineduseofhe4ca125ca199andceainovariantumors
AT shenjing clinicalanalysisoffourserumtumormarkersin458patientswithovariantumorsdiagnosticvalueofthecombineduseofhe4ca125ca199andceainovariantumors
AT wangjianwei clinicalanalysisoffourserumtumormarkersin458patientswithovariantumorsdiagnosticvalueofthecombineduseofhe4ca125ca199andceainovariantumors
AT caipengwei clinicalanalysisoffourserumtumormarkersin458patientswithovariantumorsdiagnosticvalueofthecombineduseofhe4ca125ca199andceainovariantumors
AT huangyi clinicalanalysisoffourserumtumormarkersin458patientswithovariantumorsdiagnosticvalueofthecombineduseofhe4ca125ca199andceainovariantumors